Phaseline

Companies › Genfleet Therapeutics (Shanghai)

Genfleet Therapeutics (Shanghai): clinical trials, targets and expected readouts

4 active drug programs in 77 registered trials: 49 Phase 2, 14 Phase 1, 14 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cetuximab (GFH375)
KRAS G12D inhibitor
KRASPhase 3Metastatic Pancreatic Cancer; KRAS G12D Mutation; Pancreatic Cancer; Advanced Solid Tumors Cancer …Jun 2027
GFH276
RAS inhibitor
–Phase 2Pancreatic Cancer; Advanced Solid Tumors CancerNov 2027
GFS202A–Phase 2Pancreatic Cancer; Cancer CachexiaAug 2028
GFH009–Phase 1Large B-cell LymphomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03498378Cetuximab (GFH375)Phase 1Head and Neck Squamous Cell CarcinomaOncologyFeb 2020
NCT03493048Cetuximab (GFH375)Phase 2Colorectal CancerOncologyDec 2022
NCT03874026Cetuximab (GFH375)Phase 2Colorectal CancerOncologyMay 2023
NCT05586100Cetuximab (GFH375)Phase 2Patients With Locally Recurrent Resectable Head and Neck Squamous Cell CarcinomaOncologyApr 2025
NCT06279351Cetuximab (GFH375)Phase 2Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal CancerOncologyDec 2025
NCT06898255GFS202APhase 1Cancer CachexiaOncologyJun 2026
NCT05312398Cetuximab (GFH375)Phase 2Metastatic Colorectal AdenocarcinomaOncologyAug 2026
NCT02270814Cetuximab (GFH375)Phase 2Head and Neck CancerOncologySep 2026
NCT06998069Cetuximab (GFH375)Phase 3Head and Neck NeoplasmsOncologyDec 2026
NCT06151743Cetuximab (GFH375)Phase 2Locally Advanced Hypopharyngeal CarcinomaOncologyDec 2026
NCT01025089Cetuximab (GFH375)Phase 2ThymomaOncologyDec 2026
NCT04375384Cetuximab (GFH375)Phase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2026
NCT06005324Cetuximab (GFH375)Phase 1HPV-Negative Squamous Cell CarcinomaOncologyDec 2026
NCT05260671Cetuximab (GFH375)Phase 2Head and Neck NeoplasmsOncologyDec 2026
NCT05962502Cetuximab (GFH375)Phase 2Metastatic Colorectal CancerOncologyDec 2026
NCT05706779Cetuximab (GFH375)Phase 2Colorectal CancerOncologyDec 2026
NCT06321081Cetuximab (GFH375)Phase 2RAS MutationOncologyDec 2026
NCT06375733GFH009Phase 1Large B-cell LymphomaOncologyDec 2026
NCT06226857Cetuximab (GFH375)Phase 3Colorectal NeoplasmsOncologyDec 2026
NCT07257653Cetuximab (GFH375)Phase 2Colorectal NeoplasmsOncologyDec 2026
NCT06763029Cetuximab (GFH375)Phase 2Colorectal Cancer MetastaticOncologyDec 2026
NCT06239220Cetuximab (GFH375)Phase 2Head and Neck CancerOncologyDec 2026
NCT06978829Cetuximab (GFH375)Phase 2LA HNSCCOncologyMar 2027
NCT01468896Cetuximab (GFH375)Phase 1Metastatic Head and Neck Squamous Cell CarcinomaOncologyMar 2027
NCT04229459Cetuximab (GFH375)Phase 2Esophageal Squamous Cell CarcinomaOncologyApr 2027
NCT06411600Cetuximab (GFH375)Phase 2Metastatic Colorectal CancerOncologyMay 2027
NCT07559760Cetuximab (GFH375)Phase 2Metastatic Colorectal CancerOncologyMay 2027
NCT07262567Cetuximab (GFH375)Phase 3Metastatic Pancreatic CancerOncologyJun 2027
NCT07259590Cetuximab (GFH375)Phase 1Advanced Solid Tumors CancerOncologyJul 2027
NCT06869473Cetuximab (GFH375)Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)OncologyAug 2027
NCT07198841Cetuximab (GFH375)Phase 2Lung Cancer (Non-Small Cell)OncologySep 2027
NCT04687631Cetuximab (GFH375)Phase 3Colorectal CancerOncologySep 2027
NCT06978400Cetuximab (GFH375)Phase 2NeoplasmsOncologyNov 2027
NCT07678593GFH276Phase 1Advanced Solid Tumors CancerOncologyNov 2027
NCT02999087Cetuximab (GFH375)Phase 3HNSCCOncologyDec 2027
NCT07506109Cetuximab (GFH375)Phase 2BRAF V600EOncologyDec 2027
NCT04017650Cetuximab (GFH375)Phase 1BRAF NP_004324.2:p.V600EOncologyDec 2027
NCT01154920Cetuximab (GFH375)Phase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2027
NCT03391843Cetuximab (GFH375)Phase 2Rectal Cancer Stage IIIOncologyDec 2027
NCT07012954Cetuximab (GFH375)Phase 1Colorectal Cancer MetastaticOncologyDec 2027
NCT07063212Cetuximab (GFH375)Phase 2Squamous Cell Carcinoma of Head and NeckOncologyJan 2028
NCT06725368Cetuximab (GFH375)Phase 2Head and Neck CancerOncologyJan 2028
NCT06855212Cetuximab (GFH375)Phase 2Head and Neck Squamous Cell CarcinomaOncologyMar 2028
NCT06477692Cetuximab (GFH375)Phase 2Head and Neck CancerOncologyJul 2028
NCT06500676Cetuximab (GFH375)Phase 1KRAS G12D MutationsOncologyJul 2028
NCT07784374GFH276Phase 2Pancreatic CancerOncologyAug 2028
NCT07784374GFS202APhase 2Pancreatic CancerOncologyAug 2028
NCT07784374Cetuximab (GFH375)Phase 2Pancreatic CancerOncologyAug 2028
NCT06440902Cetuximab (GFH375)Phase 2Colorectal Cancer MetastaticOncologySep 2028
NCT05041127Cetuximab (GFH375)Phase 2ChordomaOncologySep 2028
NCT06856213Cetuximab (GFH375)Phase 2Recurrent / Metastatic Head and Neck Squamous Cell CarcinomaOncologyOct 2028
NCT07882888Cetuximab (GFH375)Phase 2Head and Neck CancerOncologyOct 2028
NCT03944941Cetuximab (GFH375)Phase 2Skin Squamous Cell CarcinomaOncologyDec 2028
NCT07581912Cetuximab (GFH375)Phase 2Colorectal CancerOncologyDec 2028
NCT02861898Cetuximab (GFH375)Phase 1GlioblastomaOncologyDec 2028
NCT04616183Cetuximab (GFH375)Phase 1Metastatic Colon AdenocarcinomaOncologyDec 2028
NCT06412198Cetuximab (GFH375)Phase 1Metastatic Colorectal CancerOncologyMar 2029
NCT06207656Cetuximab (GFH375)Phase 2Colorectal CancerOncologyApr 2029
NCT07549399Cetuximab (GFH375)Phase 3Rectal AdenocarcinomaOncologyApr 2029
NCT05863195Cetuximab (GFH375)Phase 3Metastatic Colorectal CarcinomaOncologyJun 2029

The 60 nearest readouts of 77 trials; the rest in the app.

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Companies built like this

Kumquat Biosciences Ranok Therapeutics (Hangzhou) Vividion Therapeutics Blueprint Medicines InxMed (Shanghai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.